Trial Profile
INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2020
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacodynamics
- Acronyms INTERVAL
- 16 Dec 2019 Status changed from active, no longer recruiting to discontinued.
- 05 Nov 2019 Planned End Date changed from 31 Aug 2020 to 6 Jan 2020.
- 05 Nov 2019 Planned primary completion date changed from 31 Aug 2020 to 6 Jan 2020.